Study of fruquintinib plus immunotherapy after standard CRC treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have colorectal cancer that cannot be removed by surgery and has spread to other body parts.
- Your spread is not “liver-only.” Either there is no liver involvement, or if there is liver involvement, there are also other metastases (like lung or lining-of-the-abdomen spread).
- Your tumor tests show it is mismatch-repair stable (or pMMR/MSS/low MSI) based on specific lab tests (IHC, PCR, or NGS).
- You have tried standard colorectal cancer treatment (including chemotherapy with fluorouracil/oxaliplatin/irinotecan, and certain antibody drugs when appropriate) and then the cancer worsened or you could not tolerate it.
- You must have at least one measurable cancer spot for tracking, and your blood counts and organ tests (kidney, liver, thyroid, blood clotting) need to be within allowed ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests a new drug combo (fruquintinib and sintilimab) with or without radiation for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a combination of two newer drugs plus chemotherapy as the first treatment for people with advanced colorectal cancer that has a RAS or BRAF gene change. The goal is to see if this combination helps shrink tumors and slow the cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.